Medacta Group (FRA:6MD) EBIT: €122.1 Mil (TTM As of Dec. 2025)


FRA:6MD Medacta Group SA FRA:6MD
91 GF Score
Price €143.00
GF Value €178.79
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medacta Group EBIT?

Medacta Group FRA:6MD +1.42% 91 EBIT is €122.1 Mil as of Dec. 2025. GuruFocus rates FRA:6MD with a GF Score™ of 91/100 and a GF Value™ of €178.79 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Medacta Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €40.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €122.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medacta Group's annualized ROC % for the quarter that ended in Dec. 2025 was 9.70%. Medacta Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medacta Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 3.83%.


Medacta Group  (FRA:6MD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medacta Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=102.008 * ( 1 - 24.13% )/( (769.075 + 826.208)/ 2 )
=77.3934696/797.6415
=9.70 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=917.644 - 58.225 - ( 33.211 - max(0, 216.704 - 450.029+33.211))
=826.208

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Medacta Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=80.324/( ( (342.934 + max(229.097, 0)) + (385.997 + max(302.799, 0)) )/ 2 )
=80.324/( ( 572.031 + 688.796 )/ 2 )
=80.324/630.4135
=12.74 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(117.515 + 267.36 + 16.878) - (51.003 + 0 + 121.653)
=229.097

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(121.127 + 271.415 + 23.483) - (58.225 + 0 + 55.001)
=302.799

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medacta Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=122.102/3187.880
=3.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medacta Group EBIT Related Terms


Medacta Group EBIT Historical Data

* Premium members only.

The historical data trend for Medacta Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group EBIT Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.89 58.46 65.56 95.28 122.10

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.85 53.28 42.01 81.94 40.16

FRA:6MD vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Medacta Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medacta Group EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medacta Group's EV-to-EBIT falls into.


FRA:6MD
91GF Score
Medacta Group SA FRA:6MD
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €122.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €122.1 Mil mean?
Medacta Group (FRA:6MD) has a EBIT of €122.1 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medacta Group.
Is Medacta Group's EBIT too high?
Medacta Group's current EBIT is €122.1 Mil. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's EBIT compare to ABT and SYK?
Medacta Group's EBIT of €122.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medacta Group. Medacta Group's current EBIT is €122.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €178.79, compared to a current price of €143.00 — trading 20% below its estimated fair value. The current EBIT is €122.1 Mil. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current EBIT is €122.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (FRA:6MD) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of €143.00 is trading 20% below its estimated GF Value™ of €178.79. GuruFocus considers Medacta Group to be Modestly Undervalued.

Key valuation signals for FRA:6MD:

  • EBIT: €122.1 Mil
  • GF Value™: €178.79 vs. price of €143.00 (20% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score

Get the complete analysis for FRA:6MD

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.00
Price
€178.79
GF Value